Trust Company of Vermont’s Neurocrine Biosciences NBIX Stock Holding History

Trust Company of Vermont’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-106	Closed	-$10K	–	845
2023 Q2	$10K	Hold	106	–	–	﹤0.01%	672
2023 Q1	$10.7K	Hold	106	–	–	﹤0.01%	700
2022 Q4	$12.7K	Hold	106	–	–	﹤0.01%	654
2022 Q3	$11K	Hold	106	–	–	﹤0.01%	706
2022 Q2	$10K	Buy	+106	New	+$9.78K	﹤0.01%	685

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trust Company of Vermont's NBIX Position: Q3 2023 in Review

Trust Company of Vermont sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 106 shares — an estimated $10K sold.

Trust Company of Vermont first reported a position in NBIX in Q2 2022 and held it in 5 quarters. The position peaked at $12.7K in Q4 2022. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

Trust Company of Vermont reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
Trust Company of Vermont sold 106 Neurocrine Biosciences shares in Q3 2023, an estimated $10K.
Trust Company of Vermont first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 5 quarters.
Trust Company of Vermont's Neurocrine Biosciences position peaked at $12.7K in Q4 2022.
512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Trust Company of Vermont's 13F filing for Q3 2023, filed 27 Nov 2023.